BCTX | BriaCell Therapeutics Corp. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.4970 - 0.5400
52 Week Range	0.4600 - 5.97
Beta	1.80
Implied Volatility	243.31%
IV Rank	27.46%
Day's Volume	1,072,511
Average Volume	2,459,788
Shares Outstanding	44,204,200
Market Cap	23,649,247
Sector	Healthcare
Industry	Biotechnology
IPO Date	2012-03-14

Valuation
Profitability
Growth
Health
P/E Ratio	-0.60
Forward P/E Ratio	-4.42
EPS	-0.89
1YR Price Target	20.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	16
Country	Canada
Website	BCTX

BriaCell Therapeutics Corp is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer. BriaCell, in collaboration with Incyte Corp., is conducting a Phase I/IIa clinical trial of Bria-IMT, its lead candidate, in a Combination Study with Incyte drugs, INCMGA00012, and epacadostat, in advanced breast cancer. Additionally, it is developing Bria-OTS, off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing and is designed to produce a potent and selective immune response against the cancer of each patient eliminating the time, expense and complex manufacturing logistics associated with immunotherapies.

BCTX's peers: XFOR, TERN, DAWN, PDSB, INZY, EFTR, ELEV, MREO, HEPA, HOOK, BCTXW

*Chart delayed

Analyzing fundamentals for BCTX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see BCTX Fundamentals page.

Watching at BCTX technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on BCTX Technicals page.